LEIDEN, NETHERLANDS--(Marketwire - December 18, 2008) - Leiden, The Netherlands/Parsippany, USA, 18 December 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that CSL Limited, a global biopharmaceutical company headquartered in Melbourne, Australia, signed a license agreement allowing CSL to develop protein therapeutics for multiple undisclosed disease targets on the PER.C6® platform. Under the terms of the agreement, CSL is responsible for the development of protein and antibody products resulting from this alliance. Financial terms of the agreement were not disclosed.
